• Home
  • Test Directory
  • Send Samples
  • Resources
  • R and D
  • News Room
  • About Us
  • Contact Us
A worldwide leader in specialized genetic testing. The Company’s advancements in cystic fibrosis, chronic and hereditary pancreatitis, diabetes, pulmonary diseases, and other severe genetic conditions are providing precise, cost-effective tests to aid in disease definition and early, more accurate diagnosis.
CF Support Forum

An online community celebrating 10 years of providing a wide range of information dealing with Cystic Fibrosis.
cf
Newsletter
Don't miss out on the latest news in genetic testing. Subscribe to our newsletter "Ambry Primer."
Name:
Email:
Latest News

May 1, 2008
PHOX2B sequencing begins for Congential Central Hypoventilation Syndrome

APRIL 22, 2008
Ambry Genetics Announces Next Generation Sequencing Services for Support of Pharmacogenomics Research.

MARCH 5, 2008
Insulin gene sequencing joins Neonatal Diabetes panel..

JANUARY 28, 2008
Ambry Genetics Creates New Business Division to Support Biopharmaceutical Research.

JANUARY 28, 2008
Sequencing test for Glutaric Acidemia Type 1 now available.

NOVEMBER 30, 2007
Sequencing test for Transthyretin Amyloidosis now available.

Ambry Genetics provides answers to clinicians, patients, and researchers with comprehensive, reliable, and state-of-the-art DNA diagnostic testing. The Company is well known for its Cystic Fibrosis tests, CF AMPLIFIED™ and 508 FIRST™, which detect more than 99% of the 1500-plus known CF mutations in patients of all ethnicities. With over 10,000 full analyses of the CFTR gene completed, Ambry Genetics has the largest single-laboratory database from which to draw the most experienced diagnostic conclusions. We are proud to be involved with the CF Community through our genetic testing services and relationships with support organizations.

Diabetes genetic testing at Ambry Genetics is thorough and easy with the availability of individual gene sequence analyses and cost-saving reflex pathways for diagnosis of neonatal diabetes, congenital hyperinsulinism, and MODY (Maturity-Onset Diabetes of the Young) Types 1-5.

Ambry Genetics features a unique menu of pulmonary disease genetic tests including The Ambry Test: IPF Telomerase, which is the first clinical test available to define the genetics of idiopathic pulmonary fibrosis. Mutations in Surfactant Proteins B and C, and the ABCA3 protein, cause severe neonatal respiratory distress and/or interstitial lung diseases. We also provide mutation testing for primary ciliary dyskinesia, sequencing for alpha-1-antitrypsin deficiency and pulmonary arterial hypertension, plus research testing of the ADRB2 asthma gene and Surfactant Proteins A and D.

Ambry Genetics created the first comprehensive genetic test for three principal genes (PRSS1, SPINK1, and CFTR) associated with Chronic Pancreatitis and Hereditary Pancreatitis. One in four patients has at least one significant mutation. The Ambry Test: Pancreatitis facilitates identification of genetic contributions to this disease, leading to better patient management.

Clients of Ambry Genetics benefit from expanded customer services including pre-test verification of patient insurance benefits and results discussion with on-staff genetic counselors. Our flexible Research & Development department is structured for rapid development of new tests and quick response to researchers' needs for testing in clinical studies. Ambry Genetics is committed to quality, service, patient care, and promotion of research.

Call our Client Services department at 866-262-7943 to order sample submission kits or to get additional information.